GlassScriptPhysician profile
Elizabeth E Hubert
NPI 1942897574
$8,272.34
in general payments reported to CMS, 2019-2025
24 companies · $926 in 2025
The $926 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.84 · 2022: $255 · 2023: $492 · 2024: $6,575 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,708 · Food and Beverage: $2,644 · Travel and Lodging: $2,571 · Education: $70.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,707.50 |
| Food and Beverage | $2,644.44 |
| Travel and Lodging | $2,570.71 |
| Education | $70.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $3,018.15 | 2022-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $3,004.60 | 2024 | |
| Novartis Pharmaceuticals Corporation | $245.29 | 2022-2025 | |
| Astellas Pharma US INC | $221.07 | 2023-2025 | Xospata, Cresemba |
| Astrazeneca Pharmaceuticals LP | $196.93 | 2021-2024 | Calquence |
| Pharmaessentia USA Corporation | $171.91 | 2023-2025 | Besremi |
| Abbvie INC. | $159.00 | 2024-2025 | |
| Cti Biopharma Corp. | $158.78 | 2022-2023 | Vonjo |
| Syndax Pharmaceuticals, INC. | $133.92 | 2025 | |
| Lilly USA, LLC | $132.24 | 2023-2025 | Jaypirca |
| Incyte Corporation | $116.22 | 2022-2025 | Jakafi |
| Sobi, INC | $111.21 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $85.30 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Glaxosmithkline, LLC. | $85.28 | 2024-2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $80.08 | 2023-2025 | Keytruda, Reblozyl, Recarbrio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $71.89 | 2022-2024 | Imbruvica |
| Taiho Oncology, INC. | $68.69 | 2024-2025 | |
| Pfizer INC. | $62.98 | 2023-2025 | |
| Apellis Pharmaceuticals, INC. | $30.29 | 2024 | Empaveli |
| Daiichi Sankyo INC. | $27.66 | 2023 | |
| Amgen INC. | $27.54 | 2023 | Blincyto |
| Servier Pharmaceuticals LLC | $24.98 | 2023 | |
| Adaptive Biotechnologies Corporation | $21.19 | 2025 | Clonoseq |
| Azurity Pharmaceuticals, INC. | $17.14 | 2025 | Danziten |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Hubert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.